Kymera Therapeutics (KYMR) Common Equity (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Common Equity data on file, last reported at $1.5 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $1.5 billion, up 95.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 95.82% YoY), and the FY2025 annual result was $1.6 billion, up 89.04% from the prior year.
• Common Equity fell to $1.5 billion in Q1 2026 per KYMR's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.6 billion in Q4 2025 and troughed at $395.0 million in Q4 2023.
• A 5-year average of $733.3 million and a median of $684.9 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity fell 22.88% in 2023, then surged 125.75% in 2024.
• A 5-year view of Common Equity shows it stood at $490.2 million in 2022, then dropped by 19.42% to $395.0 million in 2023, then surged by 111.56% to $835.6 million in 2024, then jumped by 89.04% to $1.6 billion in 2025, then retreated by 2.53% to $1.5 billion in 2026.
• Business Quant data shows KYMR's Common Equity at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $946.3 million in Q3 2025.